Evidence map›Paper›PMID 21895680›Full record

ArticleJournal of medical primatology2011

Molecularly cloned SHIV-CN97001: a replication-competent, R5 simian/human immunodeficiency virus containing env of a primary Chinese HIV-1 clade C isolate.

Qiang Liu, Yue Li, GuiBo Yang, JieJie Dai, Ruth M Ruprecht, Yiming Shao

Abstract read
In one paragraph

Article in Journal of medical primatology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Qiang LiuNational Center for AIDS/STD Control and prevention, China CDC, Beijing, China.
Yue Li
GuiBo Yang
JieJie Dai
Ruth M Ruprecht
Yiming Shao

Funding

Virology &ImmunologyU19AI051915 · NIAID · NATIONAL CENTER FOR AIDS/STD CONTROL AND PREVENTION · PI SHAO, YIMING · 2002 to 2009
$21.6M
NIAID NIH HHS U19 AI051915NIAID NIH HHS U19AI51915
6 · The paper itself

Abstract

backgroundThe increasing prevalence of human immunodeficiency virus type 1 (HIV-1) subtype C infection worldwide calls for efforts to develop a relevant animal model for evaluating AIDS candidate vaccines. In China, the prevalent HIV strains comprise a circulating recombinant form, BC (CRF07_BC), in which the envelope belongs to subtype C.

methodsTo evaluate potential AIDS vaccines targeting Chinese viral strains in non-human primate models, we constructed a simian/human immunodeficiency virus (SHIV) carrying most of the envelope sequence of a primary HIV-1 clade C strain isolated from an HIV-positive intravenous drug user from YunNan province in China. Furthermore, to determine whether in vivo adaptation would enhance the infectivity of SHIV-CN97001, the parental infectious strain was serially passaged through eight Chinese rhesus macaques.

resultsInfection of six Chinese rhesus macaques with SHIV-CN97001 resulted in a low level of viremia and no significant alteration in CD4+ T-lymphocyte counts. However, the hallmarks of SHIV infectivity developed gradually, as shown by the increasingly elevated peak viremia with each passage.

conclusionThese findings establish that the R5-tropic SHIV-CN97001/Chinese rhesus macaque model should be very useful for the evaluation of HIV-1 subtype C vaccines in China.

Indexed as

Disease Models, AnimalMacaca mulattaAcquired Immunodeficiency SyndromeAnimalsCD4 Lymphocyte CountCD4-Positive T-LymphocytesChimeraCloning, MolecularFlow CytometryGene Products, envHIV-1HumansInjections, IntravenousProvirusesReal-Time Polymerase Chain ReactionReceptors, CCR5Gene Products, envReceptors, CCR5

Identifiers

PMID21895680
PMCPMC3389047

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.